133 related articles for article (PubMed ID: 12782573)
1. Magnetic resonance molecular imaging of the HER-2/neu receptor.
Artemov D; Mori N; Ravi R; Bhujwalla ZM
Cancer Res; 2003 Jun; 63(11):2723-7. PubMed ID: 12782573
[TBL] [Abstract][Full Text] [Related]
2. Investigation using an HER-2/neu transgenic mouse model of a newly developed MR contrast agent with the effect of an antitumor drug.
Sonoda A; Nitta N; Ohta S; Nitta-Seko A; Murata S; Jo J; Tabata Y; Takahashi M; Tani T; Murata K
J Magn Reson Imaging; 2009 Oct; 30(4):907-10. PubMed ID: 19787744
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
[TBL] [Abstract][Full Text] [Related]
4. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents.
Funovics MA; Kapeller B; Hoeller C; Su HS; Kunstfeld R; Puig S; Macfelda K
Magn Reson Imaging; 2004 Jul; 22(6):843-50. PubMed ID: 15234453
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
6. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
[TBL] [Abstract][Full Text] [Related]
7. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
8. Flow cytometry: a new approach for the molecular profiling of breast cancer.
Lostumbo A; Mehta D; Setty S; Nunez R
Exp Mol Pathol; 2006 Feb; 80(1):46-53. PubMed ID: 16271361
[TBL] [Abstract][Full Text] [Related]
9. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery].
Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ
Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304
[TBL] [Abstract][Full Text] [Related]
10. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles.
Artemov D; Mori N; Okollie B; Bhujwalla ZM
Magn Reson Med; 2003 Mar; 49(3):403-8. PubMed ID: 12594741
[TBL] [Abstract][Full Text] [Related]
11. [Application of biotin-avidin system in targeted magnetic resonance imaging].
Liu X; Xu YK; Ye J
Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1130-2. PubMed ID: 15485783
[TBL] [Abstract][Full Text] [Related]
12. Anti-HER-2/neu immune responses are induced before the development of clinical tumors but declined following tumorigenesis in HER-2/neu transgenic mice.
Takeuchi N; Hiraoka S; Zhou XY; Nagafuku M; Ono S; Tsujimura T; Nakazawa M; Yura Y; Hamaoka T; Fujiwara H
Cancer Res; 2004 Oct; 64(20):7588-95. PubMed ID: 15492286
[TBL] [Abstract][Full Text] [Related]
13. Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor.
Witters L; Scherle P; Friedman S; Fridman J; Caulder E; Newton R; Lipton A
Cancer Res; 2008 Sep; 68(17):7083-9. PubMed ID: 18757423
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
15. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors.
Liu JC; Deng T; Lehal RS; Kim J; Zacksenhaus E
Cancer Res; 2007 Sep; 67(18):8671-81. PubMed ID: 17875707
[TBL] [Abstract][Full Text] [Related]
16. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice.
Provinciali M; Papalini F; Orlando F; Pierpaoli S; Donnini A; Morazzoni P; Riva A; Smorlesi A
Cancer Res; 2007 Mar; 67(5):2022-9. PubMed ID: 17332330
[TBL] [Abstract][Full Text] [Related]
17. Targeted magnetic resonance imaging with intraperitoneal and intravenous streptavidin (SA)-DTPA-Gd: a comparative study in tumor-bearing nude mice.
Ye J; Xu YK; Liu X; Lü GS
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Feb; 26(2):139-43. PubMed ID: 16503514
[TBL] [Abstract][Full Text] [Related]
18. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
19. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Dragowska WH; Warburton C; Yapp DT; Minchinton AI; Hu Y; Waterhouse DN; Gelmon K; Skov K; Woo J; Masin D; Huxham LA; Kyle AH; Bally MB
Mol Cancer Res; 2004 Nov; 2(11):606-19. PubMed ID: 15561777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]